Venable, Zuckerman, Simpson Guide Ranbaxy to $500 Million DOJ Settlement, FDA Consent Decree over Tainted Drugs

   |0 Comments

According to papers filed by the DOJ in a related case, the government's probe concerned an alleged "pattern of systemic fraudulent conduct" by Ranbaxy, including false submissions to the FDA and a coverup of safety violations at at least one Ranbaxy plant in India that allowed "the introduction of adulterated and misbranded products into interstate commerce."

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202536365285

Thank you!

This article's comments will be reviewed.